R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Zahra Mahmoudjafari, PharmD, MBA, BCOP - Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/NDY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM! Upon completion of this activity, participants should be better able to: Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents; Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM; and Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies